<DOC>
	<DOC>NCT00680953</DOC>
	<brief_summary>Evaluate the efficacy and safety of denosumab in the treatment of involutional (postmenopausal and senile) osteoporotic subjects with prevalent fragility vertebral fracture(s)</brief_summary>
	<brief_title>Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Involutional (postmenopausal and senile) osteoporosis with prevalent fragility vertebral fractures Any underlying condition,(other than BMD) that might have resulted in abnormal bone metabolism</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>